Menu
Search Close

News

News, Webcasts and interviews

Scancell raises £5mln in 'most successful round they've ever had' - CEO Richard Goodfellow

Richard Goodfellow, chief executive of Scancell Holdings Plc (LON:SCLP) talks through with Proactive Investors their £5mln raise to fund clinical work on their pipeline of cancer immune-therapies.

Fri, 12 May 2017 07:57:00

Scancell Holdings raises £5mln as pace of clinical work quickens

The money will support clinical work on its pipeline of cancer immunotherapies and in particular Modi-1, the first product from its Moditope platform.

Thu, 11 May 2017 12:00:00

Scancell boss 'very excited' about collaboration deal with leading US lung cancer foundation

Scancell Holdings Plc (LON:SCLP) has confirmed it will kick off a phase II clinical trial of its potentially breakthrough cancer treatment in the second half.

CEO Richard Goodfellow also tells Proactive's Andrew Scott they've found a partner to help them with a phase I/II clinical study of SCIB2 for patients with lung cancer.

Wed, 01 Feb 2017 09:53:00

Scancell rounds up a busy six months

The update was provided as Scancell served up its financial results for the six months ended October 31.

Tue, 31 Jan 2017 08:01:00

Scancell poised for “significant” year with its immuno-oncology portfolio

The start of 2017 has seen some good trial results for its skin cancer treatment, as well as a collaboration deal that will accelerate the development of its lung cancer drug

Mon, 30 Jan 2017 11:30:00

Scancell inks collaboration deal with leading US lung cancer foundation

It is teaming up with the Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J Addario Lung Cancer Foundation.

Mon, 30 Jan 2017 07:39:00

Scancell "very optimistic" about US study after "compelling" melanoma trial results

Richard Goodfellow, chief executive officer at Scancell Holdings Plc (LON:SCLP), the developer of novel immunotherapies for the treatment of cancer, talks to Proactive Investors about the “compelling” results from the group's clinical study on a drug for patients suffering from late-stage melanoma.

"These are very powerful data on survival and disease recurrence which are quite unlike, we believe, anything that had previously been seen in other studies," he says.

"We never really expected to be treating patients for so long," he explains. "that is how we discovered patients living up to five years with the disease, which was a surprising finding."

As the group embarks on a clinical trial in the US this year, Goodfellow believes the trial will be successful because "there is tremendous logic to the combination" and says he is "very optimistic" about the study.

Wed, 04 Jan 2017 12:08:00

Scancell hails "compelling" results from clinical trial

The study showed the response to SCIB1 was “significantly stronger” at higher doses, while the drug worked better for those patients who already had the tumour removed before treatment.

Tue, 03 Jan 2017 12:15:00

Scancell boss “very optimistic” about latest drug candidate

Richard Goodfellow, chief executive at drug research firm Scancell Holdings Plc (LON:SCLP), tells Proactive Investors that he has high hopes for the company’s latest drug candidate, SCIB2.

“We’re very optimistic [about SCIB2] and that’s based upon new understanding around how the immune system works, to allow us to manipulate it to improve the prognosis of those patients,” he says.

Goodfellow explains that the lung cancer treatment did “all that we hoped it would in animals” and the company is now preparing SCIB2 for a Phase I clinical trial, which he says has already been designed.

Touching on the company’s lead product, SCIB1, Goodfellow says the skin cancer treatment is showing “remarkable” signs in its latest trials.

He also adds that he was “delighted” after Japanese biologist Yoshinori Ohsumi recently scooped the Nobel Prize for medicine for his work on autophagy, which links in closely with Scancell’s own research.

Mon, 10 Oct 2016 13:30:00

Scancell up 7% after lung cancer announcement

With the aim of heightening its efficacy, SCIB2 will be given with a new breed of cancer treatment called a checkpoint inhibitor.

Mon, 10 Oct 2016 14:05:00

Scancell wants to take more discoveries into the clinic

The board believes that further clinical studies could add significant value to the company and is continuing to explore a number of funding options to ensure that the company has the resources to progress these programmes further - chairman, Dr John Chiplin..

Fri, 16 Sep 2016 05:38:00

Scancell adds heavy hitter to board

Dr Alan Lewis brings "a wealth of industry experience, both commercially and financially," said Scancell chairman Dr John Chiplin

Mon, 22 Aug 2016 06:35:00

Scancell says Ichor deal extension “clears the runway”

Cancer-focused immunotherapy specialist Scancell Holdings Plc (LON:SCLP) has been granted a further extension to its option to license the commercial use of Ichor Medical Systems' proprietary TriGrid electroporation delivery system with SCIB1, Scancell's ImmunoBody vaccine for the treatment of melanoma.

The extension has been granted at no cost to Scancell, chief executive officer Richard Goodfellow told Proactive Investors.

The two technologies work well together to create T-cells that are highly effective in combating cancer.

“Our technology is validating them and their technology is validating us in a way,” Goodfellow said, which may explain why Ichor was keen for Scancell to continue using the system.

“This extension of two years gives us confidence to embark upon the next round of clinical trials that we’re planning in the United States,” Goodfellow declared.

The company is talking on new people in the US and making a bigger splash across the pond, which is engendering a “much broader knowledge of the company within the biotech field”, Goodfellow said.

Wed, 20 Jul 2016 14:31:00

Scancell ever closer to tackling most deadly form of cancer

With cases of skin cancer on the rise, Scancell's immunotherapy study data has come at the right time, but is it enough to offset the insecurity in the sector?

Thu, 21 Jul 2016 09:20:00

Scancell turns to Belgian group to replenish vaccine stocks

Scancell wants the drugs for a US clinical study of SCIB1 in combination with a checkpoint inhibitor

Thu, 21 Jul 2016 06:38:00

Scancell extends commercial licence with Ichor

Scancell will continue to use Ichor’s electroporation delivery system in conjunction with its flagship skin cancer vaccine.

Wed, 20 Jul 2016 05:19:00

Scancell’s cancer vaccine programme boosted by scientific review

“We believe this platform has the potential to develop a new class of immuno-oncology therapeutics and look forward to progressing our first vaccine into the clinic as soon as possible."

Wed, 13 Jul 2016 05:25:00

Scancell Holdings says SCIB1 survival data is compelling

Chief executive Dr Richard Goodfellow told investors that the drug continues to deliver compelling survival data in patients

Wed, 06 Jul 2016 07:31:00

Scancell's SCIB1 offers patient opportunities - Panmure's Mitchell

Dr Mike Mitchell, healthcare analyst at Panmure Gordon, remains excited about Scancell Holdings Plc’s (LON:SCLP) flagship cancer drug SCIB1 in spite of the company withdrawing the current batch. 

He says Scancell did so as some of the material had been stored for over seven years and fallen out of the original specification. “

Effectively what you’ve got is a dose that perhaps doesn’t have as much of the expected dose of the active agent as would be anticipated.”

Mitchell highlights the “very good side effect profile,” of the cancer drug adding “SCIB1 in particular and the wider platform for Scancell holds some very interesting opportunities and potential for cancer patients in otherwise very difficult to treat indications.”

Fri, 17 Jun 2016 11:13:00

Scancell working quickly to secure new supplies of drug

The company said that quality control analysis revealed the “stored drug product is no longer within the original specification”.

Fri, 17 Jun 2016 13:27:00

Scancell's immunotherapy platform to fight brain cancer

Glioblastoma multiforme is one of the most common and most aggressive forms of brain cancer.

Thu, 02 Jun 2016 06:42:00

Combined immunotherapies provide hope for skin cancer cure

Cancer researchers have combined two immunotherapies to completely eradicate cancer.

Wed, 01 Jun 2016 07:54:00

Scancell undergoes management reshuffle

Scancell pursues a management reshuffle to support growth plans outlined in its latest fundraiser.

Wed, 18 May 2016 06:13:00

Scancell Holdings PLC brings in £6.2mln in fundraise

Scancell Holdings PLC revealed it had raised a total of around £6.2mln from its open offer and share placing. n.

Mon, 04 Apr 2016 08:59:00

Scancell Holdings PLC 'delighted' with success of £6.1mln fundraiser

The cash will be used to accelerate the development of both the ImmunoBody and Moditope platform technologies that help the body’s own immune system fight cancer.

Fri, 01 Apr 2016 05:56:00

Scancell Holdings PLC to present at World Vaccine Congress

Dr Peter Brown, Scancell's clinical and scientific consultant on Immunotherapeutics, will give a presentation entitled: "SCIB1 ImmunoBody stimulates a potent T cell response that eradicates tumours and prevents recurrence".

Wed, 23 Mar 2016 07:59:00

Scancell Holdings PLC’s technology underpinned by latest deal, says joint chief

Immunotherapy group Scancell Holdings PLC (LON:SCLP) is teaming up with Sweden’s leading research organisation Karolinska Institutet – run by the 2011 chair of the Nobel Assembley at Karolinska - Lars Klareskog.

The firm said it hopes will aid the development of one of its two breakthrough technologies and Richard Goodfellow, joint chief executive, speaks to Proactive about the collaboration.

He says the tie-up “really underpins the quality of the technology at Scancell”, adding that the experience and knowledge of Klareskog and his team will “strengthen” its science.

Fri, 11 Mar 2016 12:36:00

Scancell Holdings PLC teams up with Sweden's leading research organisation

Discussions with the rheumatology unit at Karolinska Institutet will explore the role of citrullinated proteins in the treatment of cancer.

Fri, 11 Mar 2016 08:12:00

Scancell PLC in collaboration talks after funding, says joint chief

Immunotherapy group Scancell PLC (LON:SCLP)  saw strong support from institutions for its fundraise to develop its two lead platform technologies.

Richard Goodfellow, joint chief executive, tells Proactive the funds will be split between its vaccine platform, Immunobody, and its pre-clinical peptide-based vaccine platform Moditope.

He adds that the company is “talking to a range of companies about a whole range of projects and you can expect to hear about the progress on various forms of collaborations over the course of this year.”

Thu, 10 Mar 2016 13:34:00

Scancell PLC fund raise well-backed as trial pace quickens

A hot area of cancer research at present, immunotherapy uses the body's own internal biological defences to ward off the disease,

Wed, 09 Mar 2016 16:04:00

Webcasts, Interviews and Media Coverage

Scancell raises £5mln in 'most successful round they've ever had' - CEO Richard Goodfellow

Richard Goodfellow, chief executive of Scancell Holdings Plc (LON:SCLP) talks through with Proactive Investors their £5mln raise to fund clinical work on their pipeline of cancer immune-therapies.

Fri, 12 May 2017 07:57:00

Scancell Holdings raises £5mln as pace of clinical work quickens

The money will support clinical work on its pipeline of cancer immunotherapies and in particular Modi-1, the first product from its Moditope platform.

Thu, 11 May 2017 12:00:00

Scancell boss 'very excited' about collaboration deal with leading US lung cancer foundation

Scancell Holdings Plc (LON:SCLP) has confirmed it will kick off a phase II clinical trial of its potentially breakthrough cancer treatment in the second half.

CEO Richard Goodfellow also tells Proactive's Andrew Scott they've found a partner to help them with a phase I/II clinical study of SCIB2 for patients with lung cancer.

Wed, 01 Feb 2017 09:53:00